94
Oct 20 (Reuters) – NanoViricides Inc: * NANOVIRICIDES: CLINICAL LEAD DRUG NV-387 HAS SHOWN STRONG ACTIVITY AGAINST MEASLES VIRUS IN A HUMANIZED ANIMAL MODEL * NANOVIRICIDES: NV-387 CAN NOW BE MADE AVAILABLE FOR EMERGENCY USE APPLICATION IN MEASLES PATIENTS TO RESPOND TO SPREADING MEASLES OUTBREAKS * NANOVIRICIDES: NV-387 HAS ALREADY COMPLETED PHASE I CLINICAL TRIAL IN HEALTHY SUBJECTS WITH NO REPORTED ADVERSE EVENTS Further company coverage: ;))
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
